| DC9512 |
Lazabemide
Featured
|
Lazabemide(Ro 19-6327/000) is selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively).
|
|
| DC22765 |
LB-102
Featured
|
LB-102 (LB-1.2, LB 102) is a a selective dopamine D2/3/5-HT7 inhibitor. |
|
| DC21221 |
LB42908 |
LB42908 is a highly potent, selective, orally active inhibitor of Ras farnesyltransferase (FTase) with IC50 of 0.9 nM against H-Ras and 2.4 nM against K-Ras.. |
|
| DC21219 |
LBL1 |
LBL1 (Lamin A inhibitor LBL1) is a novel pyrroloquinazoline compound with significant anticancer activity, targets nuclear lamins and binds to the coiled-coil domain of lamin A (Kd=5.11 uM). |
|
| DC22135 |
LC-1028 |
LC-1028 (LC1028) is a novel potent selective, covalent and irreversible inhibitor of p97 (valosin-containing protein), remains essentially irreversible ac tivity against p97 mutant C522A.. |
|
| DC21222 |
LCB 03-0110 |
LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk. |
|
| DC21223 |
LCB 03-0110 dihydrochloride |
LCB 03-0110 is a potent, ATP-competitive inhibitor of Discoidin domain receptor (DDR) family and c-Src tyrosine kinase family, as well as Btk and Syk. |
|
| DC23329 |
LCH 7749944
Featured
|
LCH 7749944 (GNF-PF-2356) is a novel and potent PAK4 with IC50 of 14.93 uM, shows weak activity against other PAK family members. |
|
| DC7184 |
Lcl-161
Featured
|
LCL161 is an oral small molecule antagonist of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies. |
|
| DC20006 |
LCL521 |
LCL521 is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase). |
|
| DC21225 |
LCS-1 |
LCS-1 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.5 uM. |
|
| DC21226 |
LCS-1.28 |
LCS-1.28 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.05-1.6 uM. |
|
| DC21227 |
LCS-1.34 |
LCS-1.34 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.1 uM. |
|
| DC21228 |
LDD1937 |
LDD1937 is a novel potent FLT3 inhibitor with IC50 of 3 nM, displays >170-fold selectivity over JAK2/3, c-MET, IRAK-4. |
|
| DC20433 |
LDHA-IN-104 |
LDHA-IN-104 is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50 of 0.87 uM, less potent for LDHB (IC50=6.9 uM). |
|
| DC21230 |
LDK1229 |
LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM. |
|
| DC5167 |
Ceritinib(LDK378)
Featured
|
LDK378 is a highly selective ALK inhibitor with IC50 of 2 nM |
|
| DC23787 |
LDN 91946 |
LDN 91946 is a selective, uncompetitive ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor with Ki of 2.8 uM, exhibits no activity against other cysteine hydrolase (UCH-L3, TGase 2, papain and caspase-3).. |
|
| DC22459 |
LDN-109657 |
LDN-109657 is a novel SMN2 modulator that increase SMN protein levels in 3813 fibroblasts by twofold at 370 nM.. |
|
| DC8231 |
LDN-192960 2HCl
Featured
|
LDN-192960 is a potent and selective inhibitor of haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase). IC50 = 0.010 µm |
|
| DC7452 |
LDN-211904 |
LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors. |
|
| DC7586 |
LDN-212854
Featured
|
LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively. |
|
| DC22460 |
LDN-75654 |
LDN-75654 is a novel potent SMN2 modulator (EC50=1.8 uM. |
|
| DC22461 |
LDN-76070 |
LDN-76070 is a novel potent SMN2 modulator (EC50=8.3 uM. |
|
| DC7947 |
Ledipasvir
Featured
|
Ledipasvir(GS5885) is an inhibitor of the hepatitis C virus NS5A protein. Ledipasvir is an experimental drug for the treatment of hepatitis C. |
|
| DC12387 |
Lefamulin acetate
Featured
|
Lefamulin acetate is a pleuromutilin antibiotic that is being developed by Nabriva Therapeutics for the treatment of acute bacterial skin and skin-structure infections. |
|
| DC8172 |
Lefamulin(BC-3781)
Featured
|
Lefamulin is a semi-synthetic compound that inhibits the synthesis of bacterial protein, which is required for bacteria to grow. |
|
| DCAPI1333 |
Leflunomide |
Leflunomide |
|
| DC21231 |
LEI-105 |
LEI-105 is a potent, highly selective, and reversible dual DAGL-α/DAGL-β inhibitor with pIC50 pf 7.5/7.4 respectively. |
|
| DC22136 |
LEI 110
Featured
|
LEI110 (LEI－110) is a potent Phospholipase A2 group XVI (PLA2G16) inhibitor with Ki of 20 nM, also has activity on HRASLS2, RARRES3 and iNAT (pIC50=6.8-7.6). |
|
